APA (7th ed.) Citation

M, O., G, S., R, K., Y, Y., K, T., M, K., . . . N, S. (2025). Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Hepatology international, 19(6), 1371. https://doi.org/10.1007/s12072-025-10875-7

Chicago Style (17th ed.) Citation

M, Ohara, et al. "Three-year Overall Survival in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab." Hepatology International 19, no. 6 (2025): 1371. https://doi.org/10.1007/s12072-025-10875-7.

MLA (9th ed.) Citation

M, Ohara, et al. "Three-year Overall Survival in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab." Hepatology International, vol. 19, no. 6, 2025, p. 1371, https://doi.org/10.1007/s12072-025-10875-7.